Checkpoint therapies are designed to target T cells,[3, 63] and T cells play a pivotal role in the effectiveness of ICIs.[3, 64, 65, 66] Tumor‐infiltrating lymphocytes (TILs) have emerged as an early and reliable indicator of ICI efficacy.[67, 68, 69] TILs, particularly CD8+ cytotoxic T cells, are commonly associated with a more inflamed TME and improved therapeutic outcomes. The gene discussed is CD8A; the disease is neoplasm.